Neurology CRO Market to Double by 2032, Reaching US$ 14.2 Bn - Persistence Market Research

The global neurology contract research organization (CRO) market is expanding at a robust pace, driven by increasing demand for outsourcing clinical research and development activities in neurology. In 2021, the market was valued at US$ 7 Bn and is forecasted to nearly double by 2032, reaching US$ 14.2 Bn. This translates to a compound annual growth rate (CAGR) of 6.7% during the forecast period of 2022 to 2032. Key factors such as the rising prevalence of neurological disorders, the surge in clinical trials targeting neurological conditions, and cost-efficiency offered by CRO services are central to this market growth.

Among all services, clinical services held the leading segment in 2021, accounting for US$ 2.2 Bn. Geographically, North America-particularly the U.S.-is the dominant market, commanding over 80% of the regional share. This is attributed to a high prevalence of neurological conditions such as Alzheimer's and Parkinson's diseases, a strong presence of top CROs, and increased healthcare R&D investments. With more than 11,000 ongoing neurology-related clinical trials, the market's momentum is expected to remain strong through 2032.

Get a Sample Copy of Research Report (Use Corporate Mail id for Quick Response):
https://www.persistencemarketresearch.com/samples/33149

✦ Key Highlights from the Report

✦ The global neurology CRO market is projected to reach US$ 14.2 Bn by 2032, growing at a CAGR of 6.7%.

✦ Clinical services dominated the market, valued at US$ 2.2 Bn in 2021.

✦ Data management services held 18.6% of the market share in 2021.

✦ The U.S. accounted for 80.9% of the North American neurology CRO market.

✦ China captured 18.4% share of the global market in 2021.

✦ Neurology-focused studies represented 51.3% of the total study share in 2021.

Market Segmentation

The neurology contract research organization market is segmented based on service, study type, indication, and end user. In terms of services, the market is dominated by clinical services, which encompass early-phase to late-phase trials including IDE, IND, PMA, and 510(k) clinical studies. Data management, regulatory affairs, and medical and scientific writing are additional pivotal services, particularly valued for their role in ensuring regulatory compliance and accelerating timelines.

By study type, the market is bifurcated into neurology-focused and neuroscience-focused studies. The neurology-focused segment leads due to increasing cases of neurological conditions such as epilepsy, Alzheimer's, and multiple sclerosis. Indication-wise, the market is driven by studies related to Alzheimer's Disease, schizophrenia, epilepsy, depressive disorders, and brain tumors, among others.

In terms of end users, pharmaceutical and biopharmaceutical companies constitute the largest share at 31.6%. These companies increasingly outsource trials to CROs to reduce in-house costs, streamline development timelines, and access expert services in complex neurological domains.

Regional Insights

North America

North America remains the most significant contributor to the global neurology CRO market. The U.S., in particular, leads the charge with an 80.9% share in 2021, largely due to a high burden of neurological diseases, significant R&D spending, and the presence of top CRO firms. The country is also at the forefront of clinical trials, with thousands focused on neurology, supported by institutions like the U.S. National Library of Medicine.

Europe

In Europe, the U.K. holds a prominent position, with a 22.9% market share in 2021. Outsourcing in the region is growing as companies aim to manage pricing pressures and navigate complex drug development pathways. The U.K.'s robust biotech landscape and active investment in clinical research infrastructure are enhancing market prospects.

Asia-Pacific

China has emerged as a high-growth region, commanding an 18.4% share in 2021. The shift of global pharmaceutical companies closing their in-house R&D operations in favor of cost-effective outsourcing to Chinese CROs is a key driver. Local players like Pharmaron Beijing Co., Ltd. are seeing rapid revenue growth, driven by demand for affordable, high-quality neurology research services.

Market Drivers

The market is strongly propelled by the increased prevalence of neurological disorders, including Alzheimer's, Parkinson's, multiple sclerosis, and epilepsy. This medical burden is prompting pharmaceutical companies to escalate drug development efforts. Another major driver is the cost-efficiency of outsourcing to CROs, which saves internal resources while providing access to specialized expertise and global trial capabilities. The surge in neurology-related clinical trials-over 11,000 currently active-is another testament to the market's vibrancy. Additionally, the regulatory complexity of global trials encourages the use of CROs that have dedicated compliance teams.

Market Restraints

Despite a promising outlook, the market faces significant challenges-particularly the scarcity of skilled professionals. Specialized roles like neuroscientists and regulatory affairs experts are in short supply. CROs must compete with pharmaceutical and academic institutions for top talent, which limits their scalability and can delay projects. This talent shortage is especially critical in regions with fewer academic institutions dedicated to neuroscience research.

Market Opportunities

The rise in outsourcing trends, particularly in emerging economies, opens substantial growth avenues. Countries like India and China are gaining favor as outsourcing destinations due to lower operational costs and a growing pool of trained researchers. Moreover, technological advancements in data analytics, digital trial recruitment, and AI-enabled patient monitoring offer CROs the opportunity to enhance their service offerings. Increased government and private funding in neuroscience further strengthens the investment case for CROs.

✔ Reasons to Buy the Report

✔ Gain detailed insights into the global and regional neurology CRO market trends and forecasts through 2032.
✔ Understand key service and study segments shaping market dynamics and driving innovation.
✔ Analyze competitive strategies, including recent mergers, collaborations, and expansions.
✔ Identify high-potential markets and emerging opportunities for CRO services.
✔ Leverage data-backed insights to support investment, partnership, and expansion decisions.

🏢 Company Insights

• Charles River Laboratories
• Laboratory Corporation of America Holdings
• IQVIA Inc.
• Syneos Health
• Parexel International Corporation
• ICON Plc.
• Medpace
• Axon CRO
• Thermo Fisher Scientific Inc. (PPD Inc.)
• CTI Clinical Trial & Consulting
• Pharmaron Beijing Co., Ltd.
• Neuroservices-Alliance
• QPS Neuropharmacology
• MD Biosciences
• Atlantic Research Group, Inc.
• EphyX Neuroscience
• Ergomed plc
• Neuron Experts

Recent Developments

• In January 2020, Charles River partnered with Takeda Pharmaceutical Company to boost neuroscience drug discovery initiatives.

• In September 2021, Syneos Health acquired StudyKIK to expand its capabilities in tech-enabled clinical trial patient recruitment.

Conclusion

The neurology contract research organization market is entering a phase of transformative growth. Bolstered by increasing neurological disease burdens, the surge in outsourcing by pharmaceutical companies, and the need for cost-efficient research solutions, the industry is well-positioned to scale. The clinical services segment will continue to dominate, while regions like North America and Asia-Pacific will serve as growth epicenters. However, addressing talent shortages and maintaining regulatory excellence will be essential for long-term success. With technological integration and expanded global footprints, CROs are set to play a pivotal role in shaping the future of neurological healthcare research.

Contact Us:
Persistence Market Research
G04 Golden Mile House, Clayponds Lane
Brentford, London, TW8 0GU UK
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

This release was published on openPR.